Lupus patients get hope from Cancer-Fighting cell therapy

NCT ID NCT05858684

Recruiting now Disease control Sponsor: RenJi Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing a new treatment called GC012F (CD19-BCMA CAR-T cells) for people with severe lupus that hasn't improved with standard medications. The therapy uses a patient's own immune cells, modified to target and destroy faulty B cells driving the disease. The main goal is to check safety and find the right dose in 18 participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GC012F injection (CD19-BCMA CAR-T cells)
What this could lead to: If it works, this could point toward a new treatment option for people with severe lupus that hasn't responded to other therapies.
What could go wrong: This is a very early, small trial (18 people) focused on safety, not yet on effectiveness. CAR-T therapy can cause serious side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CAR-T CELL THERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CAR-T CELL THERAPY

Contacts and locations

Locations

Department of Rheumatology, Ren Ji Hospital South Campus, School of Medicine, Shanghai JiaoTong University
RECRUITING

Shanghai, Shanghai Municipality, 200001, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.